S&P 500 7559.45 +0.21%
NASDAQ 26226.06 +0.07%
TASI 10808.43 -0.42%
Oil (WTI) 71.59 -0.68%
Oil (Brent) 76.06 -0.31%
VIX 15.59 -1.58%
Gold 4112.90 -0.67%
USD/SAR 3.75 +0.01%

CRISPR Therapeutics AG

CRSP · Healthcare · · USD
53.46 USD
0.00 (-5.11%)
● Updated 2026-07-10 17:11 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score HOLD Short-term (Swing)

50
/ 100
Technical 50
Trend & RS 40
Momentum 52
Fundamental (0%) 33
Macro 71
Liquidity 27
ComponentScoreWeight
Technical 50.0 40%
Trend & RS 39.7 20%
Momentum 52.1 20%
Fundamental 33.3 0%
Macro 71.2 15%
Liquidity 27.2 5%

Trade Setup

Entry 54.39
Stop Loss 47.65 (12.4%)
Target 1 (1:1) 61.13 (+12.4%)
Target 2 (2:1) 67.87 (+24.8%)
ATR(14) 3.37 (6.2%)
Risk per Share 6.74
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 75.4 +1.01
Momentum 52.1 +0.08
Quality 40.0 -0.40
Composite 55.8

Quality Scores

Piotroski F-Score 3 /9 — Weak
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Undervalued

MetricStockSectorvs Peers
P/E Ratio N/A 22.0 Inline
P/B Ratio 2.8 4.0 Below

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Position Sizing — Kelly Criterion

4.8%
Recommended Size
32.79%
Full Kelly
16.4%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 50/100. Estimated win rate 55%, avg win 8.0%, avg loss 4.0%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

RECOVERY Regime: RECOVERY (20% confidence) — position size reduced 4%

Signal Summary BUY

2
Bullish Signals
2
Bearish Signals
48.08
RSI(14)
1.4073
MACD

Relative Strength (RS) WEAK RS

24
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY → FLAT (-5.8% vs SPY 3M)
RS vs Sector INLINE (Healthcare)
RS New High No (4d since high)
Sector Outperformance +1.9% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
WEAK RS: Underperformer — the stock is lagging the market. Avoid until RS trend reverses upward.

Technical Indicators

IndicatorValueSignal
Rsi 48.08 NEUTRAL
Macd 1.4073 BULLISH
Ma Cross 53.31 / 55.49 DEATH CROSS
Trend Short ABOVE SMA50
Trend Long BELOW SMA200
Bollinger MIDDLE
Volume 0.2x LOW

Key Levels

LevelPrice
52-Week High78.48
Bollinger Upper61.61
SMA(200)55.49
SMA(50)53.31
SMA(20)55.09
Current Price53.46
Bollinger Lower48.57
52-Week Low44.12
ATR(14)3.37

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

ACCUMULATION E Confidence
50%
Acc: 1.0  |  Dist: 1.0  |  Markup: 0.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-07-06 Normal 1.25x Normal bar — no special VSA pattern
2026-07-07 Normal 1.02x Normal bar — no special VSA pattern
2026-07-08 Normal 0.75x Normal bar — no special VSA pattern
2026-07-09 Normal 0.87x Normal bar — no special VSA pattern
2026-07-10 Normal 0.2x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 58.30 Above Kijun
Kijun-sen (26) 56.23 Base line
Senkou A 57.27 Leading span A
Senkou B 55.19 Leading span B
Cloud 55.19 – 57.27 Bullish (Green)
Price vs Cloud 54.39 Below Cloud
Chikou Span 52.08 Bullish
Alignment Score 3/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BEARISH
BB: 48.57 – 61.61  |  KC: 50.3 – 59.88

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Regular Bearish RSI 25

Anchored VWAP

VWAP: 53.29 Anchor: 2026-03-30 (52w Low) ABOVE AVWAP +2.1%

Heikin-Ashi Trend

BEARISH Full data via /api/advanced/CRSP

Valuation

MetricValue
Market Cap5.26B
P/E (TTM)N/A
Forward P/EN/A
P/B2.84
EPS-6.17

Financial Health

MetricValue
Revenue Growth68.6%
Profit MarginN/A
ROE-31.2%
Debt/Equity43.41
Current Ratio17.96
Dividend YieldN/A
Payout RatioN/A
Beta1.70

Trading Data

53.46
Open
53.46
Day High
53.46
Day Low
250.7K
Volume (0.1x avg)

Recent News (8)

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Zacks · 2026-07-09
Vertex’s Crinetics Deal Balances Growth with Integration Risk
MarketBeat · 2026-07-08
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside
Trefis · 2026-07-08
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Motley Fool · 2026-07-08
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
Zacks · 2026-07-07
Over 2 Billion Reasons to Love CRISPR Therapeutics Right Now
Motley Fool · 2026-07-07
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
Motley Fool · 2026-07-07
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 2026-07-06

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —